Microsurfaced Grafts in Deep Burn Wounds

Overview

This study is designed as a prospective, randomized, within subject controlled design to evaluate the effectiveness of Microsurfaced vs Control cadaveric grafts for coverage of acute deep-partial or full-thickness burn wounds to promote wound healing. This study will be performed in 2 parts: Time to wound bed preparedness through 6 weeks (Part A) and wound site healing, graft take and long-term scar outcomes (Part B). Subjects will be treated with both control and microsurfaced cadaveric grafts on adjacent deep-partial or full-thickness burn wounds.

Full Title of Study: “A Prospective, Randomized Study to Evaluate the Effectiveness of Microsurfaced vs Control Cadaveric Decellularized Grafts to Establish Wound Bed Preparedness in Deep Partial and Full Thickness Burn Wounds”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: August 2021

Interventions

  • Biological: Split thickness skin graft
    • standard of care graft
  • Biological: microsurfaced split thickness skin graft
    • standard of care graft that has been microsurfaced

Arms, Groups and Cohorts

  • Active Comparator: Standard of Care Dermal Graft
    • Standard of care cryopreserved cadaveric split thickness skin grafts
  • Experimental: Standard of Care Dermal Graft – Microsurfaced
    • Microsurfaced cryopreserved cadaveric split thickness skin grafts

Clinical Trial Outcome Measures

Primary Measures

  • Wound bed prep
    • Time Frame: 6 week
    • To compare wound bed preparedness/time to autograft in deep-partial and full thickness burns and burn wound healing in partial thickness burns in burn sites treated with Microsurfaced vs Control cadaveric graft-treated groups through 6 weeks post initial injury.

Secondary Measures

  • Infection
    • Time Frame: Through 12 months
    • Incidence of Infection at each treatment study visit
  • Autograft take
    • Time Frame: 2 weeks
    • Autograft take will be documented as a percentage of the graft by the physician
  • Tissue oxygenation
    • Time Frame: 2 weeks
    • Tissue oxygenation will be assessed using hyperspectral imaging
  • Tissue Oxygenation
    • Time Frame: 6 weeks
    • Change in tissue oxygenation at study burn site at the time of autografting as compared to baseline.
  • Scar assessment
    • Time Frame: 3, 6, 9, 12 months
    • Scar will be assessed using the Patient and Observer Scar Assessment Scale (POSAS)
  • Tissue oxygenation
    • Time Frame: 3, 6, 9, 12 months
    • Tissue oxygenation will be assessed using hyperspectral imaging

Participating in This Clinical Trial

Inclusion Criteria

  • Signed informed consent by patient or Legally Authorized Representative (LAR) – Subject with deep partial or full thickness burn injury due to flame burn, scald injury or contact burn – Study burn site large enough to accommodate placement of control and microsurfaced cadaveric graft (minimum 4 cm2 each) at the same location OR 2 study burn sites large enough to each accommodate control and microsurfaced cadaveric graft, respectively at minimum 4 cm2. – Total Body Surface Area burned (TBSA) total ≤30 % – Admission within 72 hours of burn injury – Non-infected wound as diagnosed by the attending physician upon admission – Treated as an outpatient or in an observational setting – 21 years of age or older Exclusion Criteria:

  • Burns involving the face – Causes other than contact burn, flame or scald injuries (i.e., electrical, chemical or frostbite) – Admission time greater than 72 hours after the injury – Wounds noted to be infected at admission – Is pregnant or plans to become pregnant – Is nursing or actively lactating – Developmental disability/significant psychological disorder that in the opinion of the investigator could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including untreated schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years. – Active alcohol or substance abuse in the opinion of the investigator that could impair the subject's participation in the study protocol or record study materials – Any medical condition or co-morbidity that in the opinion of the investigator, would prevent successful participation in the study

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Markman Biologics Corporation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Claus Brandigi, MD, Principal Investigator, Joseph M Still Research Foundation
  • Overall Contact(s)
    • Joan Wilson, 706-364-2966, joan.wilson@jmsreserachfoundation.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.